Autolus Therapeutics (NASDAQ:AUTL) Earns “Buy” Rating from Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $9.00 price objective on the stock. Needham & Company LLC’s target price would indicate a potential upside of 170.27% from the stock’s previous close.

Autolus Therapeutics Price Performance

AUTL opened at $3.33 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. Autolus Therapeutics has a 1 year low of $3.06 and a 1 year high of $7.45. The stock’s 50 day simple moving average is $3.97 and its 200 day simple moving average is $4.00. The firm has a market cap of $886.08 million, a price-to-earnings ratio of -2.87 and a beta of 2.04.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC bought a new stake in Autolus Therapeutics during the 2nd quarter valued at approximately $43,000. Bayesian Capital Management LP purchased a new stake in Autolus Therapeutics in the first quarter worth $100,000. Daiwa Securities Group Inc. raised its holdings in Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Autolus Therapeutics during the first quarter valued at $108,000. Finally, SG Americas Securities LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter valued at $127,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.